key: cord-0995875-qyi3ocie
authors: Bloch, Evan M; Crowe, Elizabeth P; Tobian, Aaron A R
title: Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
date: 2021-01-07
journal: J Infect Dis
DOI: 10.1093/infdis/jiab008
sha: bee1d4dd68f4865480c378fdf0aef05aeb444e86
doc_id: 995875
cord_uid: qyi3ocie

nan

In the current issue of The Journal of Infectious Diseases, Girardin and colleagues at the New York State Department of Health evaluate the neutralizing capacity of convalescent plasma from 196 donors [1] . Their study addresses 2 very important areas of uncertainty. First, the durability of neutralizing titers (NTs) among coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) repeat donors. Second, the correlation between neutralizing activity as assessed using a formal plaque reduction neutralization test (PRNT) with that of the Ortho Vitros severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig) G assay. Given that formal neutralizing assays (eg, PRNT) are not amenable to highthroughput blood donor screening, the Ortho Vitros SARS-CoV-2 IgG assay has been adopted by the US Food and Drug Administration (FDA) as the standard by which to qualify units of CCP under the emergency use authorization (EUA). Specifically, inventories of CCP are segregated into high and low titers based on signal to cutoff (S/C) ratios of ≥12 or <12, respectively [2] .

The study's findings support the FDA recommendations, given significantly lower PRNT titers in those units with an S/C ratio <12. By contrast, an S/C ratio ≥12 had 100% specificity and positive predictive value for NT ≥20 and NT ≥80 at the 50% PRNT level. Nonetheless, waning neutralizing activity against SARS-CoV-2 was observed over time, although at least some activity was retained for the duration of the study (>12 weeks after symptom onset). Collectively, the findings provide insight into the durability of effect that can be used to optimize the CCP donation policy.

Early in the pandemic, convalescent plasma (ie, plasma that has been collected from donors following recovery) emerged as a leading therapy for COVID-19. Reports from China suggested that it may be effective, as noted by improvement in indices of infection, both clinical (eg, survival and weaning off ventilation) and laboratory (eg, viral loads and cytokine levels) [3] [4] [5] . Convalescent plasma has been used for more than a century as postexposure prophylaxis (eg, for polio, rabies, and tetanus) and/or treatment (eg, for influenza, Argentine hemorrhagic fever) of diverse infectious diseases, including other coronavirus-associated infections (ie, SARS and Middle East respiratory syndrome) [6] .

Access to CCP in the United States was scaled up rapidly to contend with clinical demand [7] . This was achieved through a variety of mechanisms, including a national expanded access program (EAP), which was initiated by the US FDA with sponsorship from the Biomedical Advanced Research and Development Authority and coordination by the Mayo Clinic. The EAP sought to facilitate access to CCP in the United States, while collecting safety data. When the EAP formally ended in August 2020, >94 000 patients had been transfused [8] . Analysis of the first 20 000 patients who were transfused in the EAP showed CCP to be well tolerated, conferring comparable risk to transfusion of standard (ie, SARS-CoV-2 nonimmune) plasma in a population of similar clinical acuity [9] .

Transition to EUA in August 2020 has since allowed for broader access to CCP among hospitalized patients with COVID-19. During the fall 2020 surge in COVID-19 incidence, an estimated 25 000-30 000 units of CCP were transfused weekly in the United States [10] . By late 2020, >250 000 patients had already been transfused with CCP in the United States alone. The demand for CCP has yet to slow, reflecting record numbers of COVID-19 cases even as we enter 2021 [11] .

The efficacy of CCP was uncertain early in the pandemic, whereby the data that supported its use were largely gleaned from observational studies of variable quality, prompting calls for clinical trials to guide practice [12] . Multiple trials and meta-analyses have since been reported, attesting to the survival benefit of early administration (ie, relative to symptom onset) of high-titer units to patients with COVID-19 [13, 14] . By contrast, transfusion of CCP in late-stage disease has shown little benefit compared with placebo or control (eg, standard of care alone) [15, 16] . It is important to continue the ongoing randomized trials in order to fully understand the efficacy of CCP across different patient populations and settings.

Donor qualification and optimal selection of donors to ensure high-titer units of CCP remain a challenge. Certain factors have already been established, such as the association between male sex, severe disease requiring hospitalization, and advanced age with higher titers of neutralizing antibodies [17] . Neutralizing activity may be the best surrogate of functional effect, but its assessment is not amenable to high-throughput donation testing, thus forcing reliance on clinical assays. Pertinent to the current study, Girardin and colleagues [1] offer insight into the correlation with one clinical assay, the Ortho Vitros SARS-CoV-2 IgG assay, which has been used to benchmark CCP under the EUA. They also provide data on the durability of neutralizing effect.

One challenge-as acknowledged by the authors-is the neutralization assay itself, which suffers from inherent variability, limiting comparability of neutralization findings across laboratories. Similarly, the performance characteristics of the clinical assays vary [18] , explaining, in part, the seemingly disparate findings across studies. For example, one group reported a decline in antibodies 3-4 months after resolution of infection [19] , while another indicated that neutralizing effect remained robust at 5 months [20] .

Another challenge, as highlighted by Girardin and colleagues [1] , is how to meet the growing demand for CCP, while optimizing functionality within a narrow window when donor antibody titers against SARS-CoV-2 are highest. These authors suggest that there is a 6-week window (approximately 3-9 weeks after symptom onset) when recruitment would be ideal to assure collection of high-titer CCP. Unfortunately, fewer than half of donors in the study demonstrated adequate neutralizing effect approximately 3 months after initial donation. In short, it is difficult to operationalize a policy with such narrow parameters. For one, the findings suggest that repeated donation, which is foundational to safety and sustainability of the blood supply, would be time limited.

Compounding this situation, the availability of CCP will likely continue to decline as SARS-CoV-2 vaccination gains traction. Some have proposed that CCP should be collected among recently vaccinated individuals. However, questions remain unaddressed surrounding the efficacy of CCP that is collected from individuals after a vaccine-induced response and how this compares with that following natural infection. The logistics of segregating inventories accordingly are not trivial.

As Girardin and colleagues have demonstrated in the current study [1] , studying CCP continues to provide invaluable insight into the immunopathogenesis of SARS-CoV-2 [21, 22] . While their findings suggest potential modification of CCP donation, refined practice may be impractical. Despite early support for CCP, collections have been comparatively static relative to demand, thus affecting reserves of CCP [10] . With evolution of policy pertaining to CCP, there have been progressively more restrictive requirements in an effort to standardize this investigational product. At the outset, many-if not most-units of CCP were transfused without determination of titers before transfusion.

With waning inventories of CCP, as would be expected, higher Ortho Vitros IgG ratios may be correlated with higher NTs, but there are insufficient donors to sustain an inventory of high-titer units alone. Clinical trials evaluating the use of CCP as postexposure prophylaxis and early outpatient treatment are currently underway. Should these show favorable effects on morbidity and mortality rates, demand for CCP could increase dramatically. It will be important for US government regulators to work with the transfusion medicine, infectious disease, and blood donor communities to ensure a sustainable model for CCP supply through the end of the pandemic.

Financial support. This work was supported in part by National Institute of Allergy and Infectious Diseases (grants R01AI120938, R01AI120938S1, and R01AI128779 to A. A. R. T) and the National Heart Lung and Blood Institute (grant 1K23HL151826-01 to E. M. B).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Temporal analysis of serial donations reveals decrease in neutralizing capacity and justifies revised qualifying criteria for COVID-19 convalescent plasma

Re: EUA 26382: emergency use authorization (EUA) request (original request 8/12/20; amended request 8/23/20)

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Earlier the better: convalescent plasma

Deployment of convalescent plasma for the prevention and treatment of COVID-19

How did we rapidly implement a convalescent plasma program?

COVID-19 expanded access program

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

COVID-19 convalescent plasma updates

Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering at Johns Hopkins

Convalescent plasma to treat COVID-19

Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv [Preprint: not peer reviewed

Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint: not peer reviewed

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors

Cytokine and chemokine levels in COVID-19 convalescent plasma. Open Forum Infect Dis doi:10.1093/ ofid/ofaa574